Serina Therapeutics, Inc.
Moat Score — Serina Therapeutics, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Serina's POZ polymer chemistry is a patented, differentiated alternative to PEG, and the company has independent commercial validation in the form of a signed Pfizer license -- a real asset, though still a single platform with a thin track record compared to decades-proven PEG technology. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a small clinical-stage biotech with no commercial products, Serina has no manufacturing or distribution cost advantage over any competitor. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Its only live revenue stream, the Pfizer license, pays a modest tiered royalty of 2.75%-3.5% on net sales -- terms set in negotiation with a much larger partner, reflecting limited pricing leverage rather than a strong hand. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in polymer drug-delivery chemistry or in Serina's licensing model; value comes from chemistry performance, not from users or data compounding. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a partner like Pfizer builds POZ into a specific drug formulation and advances it through regulatory filings, switching to a different polymer would require costly reformulation and new trials, creating real but narrow lock-in limited to that one licensed field. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Long-acting polymer drug delivery is a specialized niche dominated by incumbent PEG technology; Serina is one of several alternative-polymer approaches competing for attention from larger pharma partners, with no clear scale-based protection of its own. |